All posts by imreal

HotelPlanner Partners with the Vegan Women Summit as their Exclusive Hotel Provider


News Image

HotelPlanner, a leading travel technology platform and hotel booking engine, today announced a service provider partnership with the Vegan Women Summit (VWS), produced in partnership with Spire, to be the exclusive hotel provider and sponsor for their flagship annual event in New York City from May 18 – 20, 2023.

The Vegan Women Summit, founded by Jennifer Stojkovic, is a leading global destination for the future of food, fashion, beauty, and beyond. With more than 50,000 members across 31 countries on six continents, the VWS mission is to inspire, educate, and empower future and rising women leaders on how to bring compassion to their career and industry. The event brings together the world’s most powerful CEOs, celebrities, athletes, investors, activists, and more, for one common purpose: empowering the next generation of women changemakers to build a kinder, more sustainable world. Previous speakers include Clueless actor Alicia Silverstone, celebrity chef Charity Morgan, actor and influencer Tabitha Brown, and Suzy Amis Cameron, founder of the One Meal a Day movement, to name a few.

“We take tremendous pride in supporting a globally recognized women’s empowerment organization and their signature event to deliver a customized hotel booking solution for all attendees,” says Philip Ballard, Chief Communications Officer, HotelPlanner. “We hope to expand this partnership in the coming years as the VWS continues to grow globally.”

“We are incredibly fortunate to have travel and hospitality experts HotelPlanner support our flagship event with curated hotels that are eco-friendly and with plant-based restaurants nearby. That’s an incredible value add to our event,” says Jennifer Stojkovic, CEO, Founder, Vegan Women Summit. “As VWS continues to expand both nationally and globally, we look forward to expanding our partnership with HotelPlanner in the future.”

“As the producer of The Vegan Women Summit, it is important to work with plant-based and eco-conscious businesses and vendors,” says Talita Trygsland, Founder & CEO, SPIRE. “Through this event, we’re working together to advance the global sustainability agenda. This is incredibly important work for our planet and industry.”

For social media promotions, please use hashtag: #VWS2023 and tag @VegWomenSummit and @HotelPlanner.

###

About Vegan Women Summit

Vegan Women Summit (VWS) is a global events and media organization created to empower women to build a kinder, more sustainable world. VWS hosts several events per year with the goal to foster conversation amongst ambitious rising leaders working to bring compassion to their careers. VWS strives to provide an inclusive environment for all. Attendees of all backgrounds and genders are invited to participate in the growing VWS community.

To learn more, visit http://www.veganwomensummit.com

About HotelPlanner

HotelPlanner is a leading travel technology company and hotel booking engine that serves all traveler hotel needs from a single platform. HotelPlanner is one of the world’s top providers of individual, group, and corporate travel bookings, specializing in unique “Closed User Group” discount rates. Founded in 2003, HotelPlanner has enduring partnerships with the world’s largest Online Travel Agencies, well-known hotel chains, individual hotels, online wedding providers, ancillary lodging providers, corporations, sports franchises, universities and government agencies.

Learn more at https://www.hotelplanner.com

Share article on social media or email:

Gladskin, a Leading Eczema Skincare Brand, Introduces New Body Lotion that Helps to Maintain and Repair the Skin Barrier for Eczema-Prone Skin


Gladskin Eczemact™ Body Lotion

Today, Gladskin, a leading international skincare brand, announced the launch of its Eczemact™ Body Lotion, which provides 24-hour hydration to dry, dehydrated, eczema-prone skin. The new body lotion is hypoallergenic, paraben-free, fragrance-free and steroid-free. It joins the suite of Gladskin’s newly branded Eczemact™ products. With science developed in Switzerland, the Gladskin brand is known for its breakthrough endolysin technology, which addresses the skin microbiome’s’ role in eczema symptoms.

“We’re thrilled to add the Eczemact™ Body Lotion to our line-up of products built for people with eczema-prone skin,” said Skyler Stein, President of Gladskin USA. “There are an estimated 31 million people in the United States¹ that have eczema, which has no cure. Our revolutionary steroid-free products, including our body lotion, are a significant advancement in OTC products for people with dry, itchy, eczema-prone skin.”

The Gladskin Eczemact™ Body Lotion is dermatologically tested, minimally formulated, hypoallergenic, and fragrance-free. Formulated with squalane and ceramides, it moisturizes, replenishes skin lipids, and strengthens the skin barrier. Its lightweight, non-greasy feel and slather-friendly size are designed for regular daily use. It is available for purchase at Gladskin.com and retails at $26. For ultimate relief, pair the Body Lotion with Gladskin’s Eczema Cream, which contains Gladskin’s patented endolysin technology Micreobalance®.

“Moisturizing and repairing the skin barrier are crucial components of eczema care,” explained board certified dermatologist Dr. Peter Lio, MD, FAAD, Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern Feinberg School of Medicine. “I recommend Gladskin’s Eczcemact Body Lotion because it’s beautifully formulated with key ingredients to support the skin barrier—and almost nothing else!”

With the release of the Body Lotion also comes the announcement of Gladskin’s newly branded Eczemact™ skincare line—a comprehensive skin- and body-care system designed for people with eczema-prone skin. The Eczemact™ line features the same great Gladskin formulas in new packaging, in addition to new products. For more details, visit Gladskin.com.

[1] National Eczema Association, https://nationaleczema.org/research/eczema-facts/

About Gladskin

Gladskin is on a mission to improve quality of life for millions of people living with inflammatory skin conditions worldwide. Our revolutionary non-prescription products for eczema and rosacea use patented endolysin science to balance the skin microbiome and restore skin health. Gladskin is a subsidiary of the European biotechnology company Micreos Group, a Dutch / Swiss biotechnology group that has pioneered the development of phage and endolysin technology as a sustainable alternative to antibiotics. Learn more at gladskin.com.

Share article on social media or email:

American Gene Technologies® CEO Jeff Galvin Wins Life Sciences Voice Top Industry Leaders Award


News Image

This is a wonderful honor, made possible thanks to the stellar collaboration and unwavering commitment of my talented colleagues and team members here at American Gene. -Jeff Galvin, CEO of AGT™

Jeff Galvin, CEO and founder of American Gene Technologies®, a clinical-stage biotechnology company based in Rockville, Maryland, has been awarded the Life Sciences Voice Top Industry Leaders Award. The award recognizes the most dynamic leaders in the life sciences industry, who are making the biggest impact in delivering transformation that is moving the industry forward. Life Sciences Voice lauds these winners as the industry’s most creative minds working on important initiatives and delivering extraordinary results.

“This is a wonderful honor, made possible thanks to the stellar collaboration and unwavering commitment of my talented colleagues and team members here at American Gene™,” said Galvin. “I am thrilled to receive this recognition for the work we have been doing using gene therapy to find cures for some of the world’s worst diseases.”

Life Sciences Voice describes this recognition as “the most prestigious leadership award in the life sciences industry.” Jean Coolidge, editor-in-chief added, “The life sciences industry, and healthcare landscape in general, continues to evolve rapidly. It has become critical for the life sciences companies and their leaders to adapt quickly and respond to the future needs of the customers.”

LSV also noted: “These leaders continue to find innovative ways to drive excellence in their field of work. They fully understand how science must be mapped to business and patient needs and are able to bring value to their stakeholders — patients, employees, healthcare partners, investors, and others.”

Having had a successful career in Silicon Valley in the ‘80s and ’90s, Galvin opted for an early retirement in 2002. But 15 years ago, National Institutes of Health researcher Roscoe Brady, MD, Ph.D, introduced him to the potential of viral vectors. Brady showed him there was a way to “repurpose” viruses from delivering disease-causing genetic elements, into delivery vehicles that could bring “good” elements into the body that fight disease. Galvin was hooked. He came out of retirement and founded American Gene.

Having been part of the computer software industry for nearly 30 years, Galvin saw many parallels between a human cell’s DNA “code” and a computer’s operating software. Viewing Dr. Brady’s work from a computer-software perspective, Galvin realized Dr. Brady had just revealed the potential of using viruses as “diskettes” that could deliver new “genetic software” into the DNA of cells to manipulate the drivers (genes) of everything in the human body.

Galvin saw Dr. Brady’s breakthrough as the beginning of a new life sciences technology revolution on a global scale, enabling gene therapy to develop along a technology “curve” that would lead to cures for thousands of diseases, including cancer. Galvin foresaw this nearly 10 years before the biotech and pharma industries began to think about the power and possibilities of gene and cell therapy.

At American Gene, Galvin prioritized the goal of curing HIV through gene therapy. He believes gene therapy can free people living with HIV from relying on lifelong antiretroviral treatments and give them permanent immunity with no chance of contracting HIV again.

Galvin views curing HIV as a proof-of-concept for American Gene’s platform, which could reduce the time and cost of developing disease-curing gene therapies by over 90% from current standards. The approach could eventually solve patient issues across infectious diseases, monogenic disorders, and cancers that affect the lives of billions of people worldwide.

About American Gene Technologies

American Gene Technologies is a gene therapy company with a proprietary gene-delivery platform for rapid development of gene therapies to cure infectious diseases, cancers, and inherited disorders. Its mission is to transform people’s lives through genetic medicines that rid the body of disease. Safety and durability data from American Gene Technologies’ Phase 1 HIV gene therapy clinical trial is published in the Frontiers in Medicine journal and a final report is being prepared for regulatory submission. In addition, the company has been granted four patents for the technology used to make AGT103-T and 11 patents for its unique immuno-oncology approach to stimulate gamma-delta (γδ) T cells to destroy a variety of solid tumors. American Gene Technologies has developed a synthetic gene for treating Phenylketonuria (PKU), a debilitating inherited disease. The company’s treatment for PKU has been granted Orphan Drug Designation by the Food and Drug Administration (FDA), and it is expected to reach the clinic in 2023.

Video About American Gene Technologies’ Work: https://youtu.be/fiA2s7JCkJ8

Share article on social media or email:

Sleeplay Announces New Mobile App Ahead of World Sleep Day


“Adapting to current technology is crucial for meeting customers where they are and increasing their accessibility to innovative products and services that improve quality of life and revolutionize sleep,” said Aaron Fuhrman, Founder and Director of Sleeplay.

Today, Sleeplay, a modern CPAP company connecting people to industry leading experts and products for the deepest, best sleep possible, launched the Sleeplay mobile application. It is now available via the App Store and Google Play Store, which will expand accessibility to its luxury sleep products, CPAP equipment and connect customers with medical experts. To celebrate the app launch and World Sleep Day on March 18, Sleeplay is offering 25% off with the promo code “APPLAUNCH25”.

“We’re thrilled to announce the launch of the Sleeplay app and expand our foothold in the CPAP and luxury sleep space,” said Aaron Fuhrman, Founder and Director of Sleeplay. “Adapting to current technology is crucial for meeting customers where they are and increasing their accessibility to innovative products and services that improve quality of life and revolutionize sleep.”

The new app will give customers access to Online CPAP Expert support, user-friendly upload RX for fast order placement, visibility into past orders and focused on removing the hassle in all things sleep, wellness and comfort. The app will provide customers with another avenue to obtain the life-changing equipment and accessories that aid the 22 million adult Americans suffering from sleep apnea or other related medical issues. Featuring hundreds of curated products for those with sleep apnea and without, like travel-size CPAP machines, CPAP cleaners, filters, tubings and CPAP batteries for camping, the new app will become the ultimate sleep playground destination.

Customers can download the IOS Sleeplay app here and the Android Sleeplay app here. To learn more about Sleeplay, visit sleeplay.com.

###

About Sleeplay

Sleeplay is a modern CPAP destination dedicated to connecting the next generation with experts and products, from CPAP machines and cleaners to masks and humidifiers, for the deepest, best sleep possible. Through its white-glove customer service and innovative smartphone app and website, Sleeplay removes the headache and hassle in discovering high-quality products by easily connecting customers with CPAP Expert and respiratory therapists to help them better understand their diagnosis and sleep needs. Sleeplay services customers looking to optimize their rest, relaxation and recovery through benefits such as digital prescription uploads, complimentary equipment troubleshooting, financing and effective diagnostic quizzes. Sleeplay proudly partners with American Homecare Equipment, Inc., a trusted member of the industry for over 30 years, and offers products from leading brands such as ResMed, Fisher & Paykel and Philips Respironics. For additional information, visit sleeplay.com.

Share article on social media or email:

Mediliant Group Announces New President of Their Facility in Plymouth, Indiana


News Image

In a continued effort to respond to customer needs and further boost company momentum, leaders in medical device contract manufacturing, Mediliant Group, has appointed industry expert Jason Ratcliffe as the new President of the organization’s CTE facility in Plymouth, Indiana.

Mr. Ratcliffe has an extensive career in the manufacturing industry, working in several key positions of increasing responsibility in the automotive, defense, and medical device industries. Based in Detroit, Michigan, Jason’s career began in the automotive industry where he spent a decade in various roles from production management, and engineering before specializing in lean manufacturing.

From here, Jason moved to Beaver Aerospace & Defense where he was the General Manager of multiple sites. Jason’s success at Beaver was a springboard into the medical device industry where he enjoyed a period of huge success as the GM of Orchid’s flagship facility, Bridgeport as well as two smaller sites, ultimately responsible for over $150m of revenue and 700 plus employees. Jason’s experience extends into procurement and sourcing, international business leadership, and people development. In his spare time, he is an owner in his church, an attentive husband and father, and an active DJ.

“We are delighted to have Jason join our team and lead our operational efforts at CTE. He is a result-orientated leader who facilitates strong, high-performing teams that have an extremely customer-focused mindset. We expect Jason to build on the excellent reputation of CTE and the strong foundations the current leadership team provides there, to deliver our strategy to become a top-tier Spine, Trauma, & Extremities contract manufacturer.” - Matt Burba, Mediliant Group CEO.

Jason’s expertise, considerable leadership and management skills, and ability to work in a high-pressure environment make him the ideal person to take Mediliant Group’s CTE facility to the next level. As the company continues to build momentum, expand capabilities, and enhance customer experiences, the growth of the leadership team plays an important role in the overall success.

For more information on Mr. Ratcliffe and the continued growth of the Mediliant Group, visit mediliant.com.

Share article on social media or email:

FDA Grants First Marketing Rights for Anthrax Point-of-Care Test to InBios


Active Anthrax Detect™ Plus Rapid Test

“A fast, accurate test is needed to prepare for a potential bioterrorism attack or outbreak. Our test could play a critical role in thwarting any suspicious activities early on.”

Given the possible severity of anthrax infection, early and fast diagnosis is key. InBios International, Inc., a leading developer of diagnostic tests for emerging infectious diseases and biothreats, has been granted the U.S. Food and Drug Administration’s (FDA) first marketing rights for an anthrax point-of-care (POC) test. This approval was granted through the FDA’s De Novo process for new medical devices or technology where there is no comparable device on the market. InBios’ Active Anthrax Detect™ Plus Rapid Test for pulmonary anthrax is for use as an aid in the diagnosis of inhalation anthrax, which occurs by breathing in anthrax spores and is the deadliest form of the disease. This test produces results in about 20 minutes and is intended for use by military personnel, medical and/or healthcare professionals only.

This in vitro immunochromatographic assay provides visual and rapid qualitative detection of the Bacillus anthracis lethal factor protein and can be used to test serum and venous whole blood (dipotassium EDTA, sodium citrate and sodium heparin) from individuals who have signs and symptoms consistent with inhalation anthrax and a likelihood of exposure. While a positive Active Anthrax Detect™ Plus Rapid Test result is presumptively diagnostic for B. anthracis infection, diagnosis of infection must be based on history, signs, symptoms, exposure likelihood, and additional laboratory evidence.

Clinical performance determined that the test had a negative percent agreement (NPA) of 100% and a positive percent agreement (PPA) of >98%. The specificity study (NPA) was conducted at three POC clinical sites in the United States, while the sensitivity (PPA) of the test was evaluated using contrived positive serum samples.

“With ease of dispersal and a high mortality rate, inhalation anthrax is a great threat to the security and safety of the world,” said Syamal Raychaudhuri, PhD, InBios Chief Scientific Officer. “A fast, accurate test is needed to prepare for a potential bioterrorism attack or outbreak. Our test could play a critical role in thwarting any suspicious activities early on.”

The De Novo classification for the Active Anthrax Detect™ Plus Rapid Test was supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number HHSO100201700029C awarded in 2017. Additionally, the Centers for Disease Control and Prevention (CDC) provided significant expertise and resources, which contributed toward the development of the Active Anthrax Detect™ Plus Rapid Test.

Anthrax is a zoonotic bacterial disease caused by Bacillus anthracis, a gram-positive, spore-forming bacterium commonly found in the soil of disease-endemic areas. The disease presents with non-specific symptoms that cannot easily be distinguished from many common diseases. Although anthrax infection is rare, risk of infection remains, whether due to bioterrorism or injectional drug usage. For more information, visit http://www.cdc.gov/anthrax.

About InBios: InBios International Inc. specializes in the design, development and manufacture of diagnostic assays for emerging infectious diseases and biothreats. InBios has several products on the market, including point-of-care tests and an over-the-counter test for COVID-19. Located in Seattle, Washington, InBios offers superior quality products which are accurate, easy to use and cost-effective. InBios is GMP compliant, FDA registered, USDA licensed, and ISO 13485:2016 certified. For more information, visit http://www.inbios.com

Share article on social media or email:

First-Ever Wheelchair Accessible Vehicle Reimagined to Honor BraunAbility’s Legacy and Mobility’s Future


Named ‘Ralph-E’ after the company’s founder, Ralph Braun, the refurbished 1961 postal Jeep bridges the company’s history of innovation to the future of personal accessible travel.

Braun didn’t realize it at the time, but his personal invention was the foundation of the automotive mobility industry and would revolutionize accessibility for people with mobility challenges around the world.

When Ralph Braun purchased an old postal Jeep in 1966, he had one goal: find a way to make it both accessible and drivable from his battery-powered scooter. Braun lived with muscular dystrophy, and the disease was gradually stealing his strength. He needed a way to get himself and his battery-powered scooter – also his own invention – to and from his job at a local factory in his hometown of Winamac, Indiana. The result was the country’s first wheelchair-accessible vehicle.

Braun didn’t realize it at the time, but his personal invention was the foundation of the automotive mobility industry and would revolutionize accessibility for people with mobility challenges around the world. In 1972, Braun founded The Braun Corporation (today known as BraunAbility), and 50 years later his company is the global leader of automotive mobility solutions.

To recognize its 50th anniversary, the company issued an internal challenge: build a mobility solution that both honored the BraunAbility’s legacy of innovation and incorporate the future of mobility technology.

The answer to the challenge was Ralph-E, a reimagining of the original postal Jeep engineered with modern mobility equipment. The team located a 1961 Jeep identical to the original chassis, a rare Willy’s FJ-3 “Fleetvan.” The Jeep’s gas engine, fuel system, steering and suspension were removed, and the new custom frame was modeled after the original. The reengineered vehicle includes:


  • Electric drivetrain from a Polaris GEM eL XD vehicle
  • 4-corner custom air kneel system
  • ADA-compliant, infloor ramp
  • BraunAbility Turny® Evo seat
  • BraunAbility/Q’Straint Omni aluminum floor
  • All-new modern steering system converted to right-hand drive
  • 4” lowered rear fender wells to accentuate the lowered floor aesthetic
  • Updated LED headlights, turn signals and brake lights

Ralph-E’s name and exterior design came from a company-wide competition, and submissions were voted on by long-time BraunAbility employees, some of whom were founding members of the company. Ralph-E is a nod to the company’s founder and the ‘E’ represents the electric drivetrain. The paint scheme reflects the original postal Jeep’s colors and includes former logos from Ralph’s company and a ghosted image of Ralph in the side windows.

Ralph-E will spend time displayed at the company’s headquarters in Carmel and Winamac, IN and is available for appearances at automotive mobility shows throughout 2023.

About BraunAbility

BraunAbility is the world’s leading manufacturer of mobility transportation solutions, including wheelchair accessible vehicles, wheelchair lifts and seating, storage and securement products. Founded nearly 50 years ago by Ralph Braun, an entrepreneur who spent most of his life in a wheelchair, the company has grown into the most well-known and trusted name in the mobility industry, bringing independence to millions of individuals across the world. BraunAbility is a wholly owned subsidiary to Patricia Industries, a division of Investor AB Group. Visit http://www.braunability.com for more information.

Share article on social media or email:

Alcatraz AI to Host Biometric Privacy Webinar to Help Enterprises Navigate Laws and Regulations to Ease Compliance and User Adoption


“Many physical security professionals and end-users greatly value the benefits of using facial authentication to reduce friction at access points, strengthen their security posture, and address the challenges of tailgating and piggybacking,” said Tad Druart, Vice President at Alcatraz AI.

Alcatraz AI, a global leader in autonomous access control solutions, today announced it is hosting a webinar to help professionals in the physical security market and corporations better understand how to successfully adopt and implement biometric access control solutions by creating a framework for communicating and managing privacy policies, procedures and compliance. Led by nationally recognized biometric privacy legal expert David Oberly of Squire Patton Boggs, the webinar will cover the latest in biometric and data privacy laws and regulations, and how to develop communications, policies, and procedures to drive compliance and ease end-user concerns.

The free webinar will be held on March 15th at 11 AM EST / 8 AM PST. If a person is unable to attend the live webinar, they can register and receive an on-demand link after the event is over.

“Many physical security professionals and end-users greatly value the benefits of using facial authentication to reduce friction at access points, strengthen their security posture, and address the challenges of tailgating and piggybacking,” said Tad Druart, Vice President at Alcatraz AI. “Recent legal challenges and confusion about biometric privacy laws have created uncertainty and some reluctance to fully deploy systems. When a company prioritizes privacy, puts the proper policies, procedures, and opt-in technology in place, and clearly communicates with employees, they can easily create an environment that is more safe and secure by using biometric solutions.”

To register and learn more visit the Privacy Webinar Registration Page.

About Alcatraz AI

Alcatraz AI uses AI and machine learning to deliver industry-leading facial authentication solutions to all access control systems to more effectively and efficiently keep people and spaces safe and secure. With its patented technology, Alcatraz AI’s facial authentication solution, intelligent tailgating detection, and simplified enrollment process work natively with existing access control systems to transform physical security and protect individual privacy. With a vision of simplicity, security, and privacy, Alcatraz AI is trusted to protect more than one million employees at Fortune 500 companies.

Share article on social media or email:

New Dermatology office opens in Muskogee, Oklahoma


Dermatologist near me

U.S. Dermatology Partners Muskogee

CEO, Paul Singh stated, “We’re delighted to offer premier dermatological services to the people of Muskogee and neighboring areas. Our new office will provide preventive care options that enhance patients’ well-being and enable the early detection of serious issues like skin cancer.”

U.S. Dermatology Partners is pleased to announce the opening of its newest office location in Muskogee, Oklahoma. The new office is part of the organization’s Outreach Program serving rural and underserved communities and will offer convenient access to dermatology and skin cancer treatments to patients in Muskogee County beginning March 1st. The office will treat patients of all ages for a range of dermatologic conditions, including acne, psoriasis, eczema, and skin cancer.

Patients seeking dermatologic treatment in rural areas may have extensive wait times or may have to travel an hour or more to reach practitioners in urban and suburban areas. U.S. Dermatology Partners is opening over 30 new locations across eight states to address this problem. New offices, like the one in Muskogee, will give patients in rural areas more accessible access to essential dermatological care. Certified Nurse Practitioner, Jenna King, will be the primary practitioner at the Muskogee office with oversight from Board-Certified Dermatologist Dr. Sara Metcalf.

U.S. Dermatology Partners CEO, Paul Singh stated, “We’re delighted to offer premier dermatological services to the people of Muskogee and neighboring areas. Our new office will provide preventive care options that enhance patients’ well-being and enable the early detection of serious issues like skin cancer when treatment is more manageable.”

Today’s announcement builds on U.S. Dermatology Partners’ recent openings of offices in Cushing, Oklahoma, Wylie, Texas, and Henderson, Texas, which expand on their efforts to reach more patients, delivering high-quality care throughout the country.

The new Muskogee office is conveniently located at 1143 N. Main Street, #B, Muskogee, OK 74401. For more information or to schedule an appointment, call (918) 537-1973 or request an appointment online.

About U.S. Dermatology Partners

U.S. Dermatology Partners is one of the largest and most sought-after dermatology practices in the country, caring for more than 1.5 million patients each year. With over 90 locations across eight states that span large metroplexes and rural, underserved communities, they provide the benefits of private, personalized levels of care paired with a network of coordinated, specialized dermatology physicians. U.S. Dermatology Partners is fervently focused on providing the highest level of compassionate and comprehensive patient-first care, making it seamless for all people to connect with dermatologists and national leaders in areas such as clinical research, psoriasis, and Mohs surgery, and gain access to state-of-the-art dermatological treatments, surgical and cosmetic dermatology. To learn more, visit usdermatologypartners.com.

Share article on social media or email:

Board-Certified Dermatologist Dr. Elizabeth Wallace Joins Cherry Hills Dermatology in Englewood, Colorado


“Dr. Wallace is an exceptional dermatologist who is nationally recognized for her work in complex medical dermatology and psoriasis, but what stands out most is her kind and gentle nature, and her ability to connect meaningfully with her patients to achieve their skin care goals.”

Elizabeth Wallace, MD, a Harvard-trained Board-Certified Dermatologist, will begin seeing patients on February 27, 2023 at Cherry Hills Dermatology. Dr. Wallace provides medical, surgical, and cosmetic care to patients of all ages.

Dr. Wallace grew up in the Bay Area of California and completed her undergraduate education at Northwestern University, graduating summa cum laude. She then went on to medical school at the University of California Davis and was inducted into the Alpha Omega Alpha honor society. Dr. Wallace completed her Internship in Medicine at the California Pacific Medical Center in San Francisco and received the “Intern of the Year” award. She then completed her Residency in Dermatology at the Harvard Combined Dermatology Program.

After completing her training at Harvard, Dr. Wallace worked as an Assistant Professor of Dermatology at the University of Colorado School of Medicine. In addition to seeing patients, Dr. Wallace was an investigator on several clinical trials studying emerging therapies for advanced skin diseases. She also co-founded the combined Dermatology/Rheumatology Clinic that provides comprehensive care to medically complex dermatology patients. Dr. Wallace is active in research and education. She has authored many publications and presented her work at local, national, and international conferences. She is on the Medical Board of the National Psoriasis Foundation and on the Colorado Dermatologic Society Board of Directors.

“We are thrilled to have a dermatologist of this stature join our team at Cherry Hills Dermatology, ” said Dr. Annelise Dawson, founder of Cherry Hills Dermatology. “Dr. Wallace is an exceptional dermatologist who is nationally recognized for her work in complex medical dermatology and psoriasis, but what stands out most is her kind and gentle nature, and her ability to connect meaningfully with her patients to achieve their skin care goals.”

Dr. Wallace lives in Denver with her husband, two children, and two goldendoodles. When she’s not treating patients, she enjoys hiking, traveling, and skiing with her family.

About Cherry Hills Dermatology

Cherry Hills Dermatology is a boutique physician-owned dermatology practice serving the Denver metro area, including Cherry Hills Village, Englewood, Greenwood Village, Littleton, and more. The practice is recognized as a leader in the local community. Patients work collaboratively with a Board-Certified Dermatologist to optimize their skin health. Cherry Hills Dermatology welcomes patients of all ages, including pediatric patients, and offers a range of medical services, including skin cancer checks, mole screening and removal, cyst removal, and evaluation and management of conditions like acne, eczema, psoriasis, and other rashes. The practice also provides a full spectrum of physician-performed cosmetic services, including Botox, fillers, laser treatments, microneedling, and skin peels.

Share article on social media or email: